Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2021 Mar;20(2):212-228.
doi: 10.1002/pst.2067. Epub 2020 Aug 29.

A stochastically curtailed two-arm randomised phase II trial design for binary outcomes

Affiliations
Clinical Trial

A stochastically curtailed two-arm randomised phase II trial design for binary outcomes

Martin Law et al. Pharm Stat. 2021 Mar.

Abstract

Randomised controlled trials are considered the gold standard in trial design. However, phase II oncology trials with a binary outcome are often single-arm. Although a number of reasons exist for choosing a single-arm trial, the primary reason is that single-arm designs require fewer participants than their randomised equivalents. Therefore, the development of novel methodology that makes randomised designs more efficient is of value to the trials community. This article introduces a randomised two-arm binary outcome trial design that includes stochastic curtailment (SC), allowing for the possibility of stopping a trial before the final conclusions are known with certainty. In addition to SC, the proposed design involves the use of a randomised block design, which allows investigators to control the number of interim analyses. This approach is compared with existing designs that also use early stopping, through the use of a loss function comprised of a weighted sum of design characteristics. Comparisons are also made using an example from a real trial. The comparisons show that for many possible loss functions, the proposed design is superior to existing designs. Further, the proposed design may be more practical, by allowing a flexible number of interim analyses. One existing design produces superior design realisations when the anticipated response rate is low. However, when using this design, the probability of rejecting the null hypothesis is sensitive to misspecification of the null response rate. Therefore, when considering randomised designs in phase II, we recommend the proposed approach be preferred over other sequential designs.

Keywords: adaptive design; cancer; continuous monitoring; interim analysis; oncology.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest

The authors declare no potential conflicts of interest.

Figures

Figure 1
Figure 1
Omni-admissible design: the approach to which the design realisation with the lowest loss score belongs, for (α, β) = (0.15, 0.2), p0 = 0.1, 0.2, 0.3, 0.4, 0.5, p1 = p0 + 0.2
Figure 2
Figure 2
Difference in loss scores for block design of size two vs other approaches, for p0 = 0.1, …, 0.5. Negative values (in red) favour block design
Figure 3
Figure 3
Difference in loss scores for block design of size eight vs other approaches, for p0 = 0.1, …, 0.5. Negative values (in red) favour block design
Figure 4
Figure 4
Probability of rejecting H0 when (p0, p1) are misspecified, for the p0-optimal Carsten design (r1, n1, r, Narm)= (1, 3, 7, 16) and block size two design (r, Narm, θF, θE) = (3, 31, 0.128, 0.932) under (α, β, p0, p1) = (0.15, 0.2, 0.1, 0.3)
Figure 5
Figure 5
Probability of rejecting H0 when (p0, p1) are misspecified, for the p0-optimal Carsten design (r1, n1, r, Narm)= (2, 7, 10, 29) and block size two design (r, Narm, θF, θE) = (5, 48, 0.115, 0.964) under (α, β, p0, p1) = (0.15, 0.2, 0.2, 0.4)

References

    1. Vickers AJ, Vennus B, Scher HI. Setting the bar in phase II trials: the use of historical data for determining “ go/no go “ decision for definitive phase III testing. Clin Cancer Res. 2007;13(3):972–976. doi: 10.1158/1078-0432.CCR-06-0909. - DOI - PMC - PubMed
    1. Grayling MJ, Dimairo M, Mander AP, Jaki TF. A review of perspectives on the use of randomization in phase II oncology trials. J Nat Cancer Inst. 2019;111:1255–1262. doi: 10.1093/jnci/djz126. - DOI - PMC - PubMed
    1. Rubinstein L, Crowley J, Ivy P, LeBlanc M, Sargent D. Randomized phase II designs. Clin Cancer Res. 2009;15(6):1883–1890. doi: 10.1158/1078-0432.CCR-08-2031. - DOI - PMC - PubMed
    1. Prasad V, Oseran A. Do we need randomised trials for rare cancers? Eur J Cancer. 2015;51(11):1355–1357. doi: 10.1016/j.ejca.2015.04.015. - DOI - PubMed
    1. Lasch F, Weber K, Chao M, Koch A. A plea to provide best evidence in trials under sample-size restrictions: the example of pioglitazone to resolve leukoplakia and erythroplakia in Fanconi anemia patients. Orphanet J Rare Dis. 2017;12:102. doi: 10.1186/s13023-017-0655-8. - DOI - PMC - PubMed

Publication types